Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.45 |
| ▸ | FNTB | P49356 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622806 | 0.82 | MAPT (0.50) | FNTAFNTBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL951773 | 0.76 | MAPT (0.53) | FNTAFNTBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL953058 | 0.76 | L3MBTL1 (0.55) | FNTAFNTBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL953048 | 0.76 | MAPT (0.53) | FNTAFNTBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL6750157 | 0.71 | MAPT (0.50) | MAPTPOLBMEN1HTTKMT2A | |
| SCHEMBL1550834 | 0.71 | PIK3CA (0.55) | FNTAFNTBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL953621 | 0.68 | CDC7 (0.49) | FNTAFNTBMAPTPOLBSMN1; SMN2 | |
| SCHEMBL12947579 | 0.67 | CYP1A2 (0.41) | MEN1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28786545 | 0.67 | MAPT (0.49) | MAPTPOLBHTTKMT2AMGAM | |
| SCHEMBL28944816 | 0.66 | USP10 (0.53) | MAPTPOLBSMN1; SMN2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-8796314-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796314-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796314-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2313399-B1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154741-A1 | THIOPHENE OR THIAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075951-A1 | Heteroaryls and uses thereof | PIK3R3, AKT1S1, PIK3R1 | FNTA 2116/4885FNTB 3061/4885MAPT 4859/4885 |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | PIK3R3, AKT1S1, PIK3R1 | FNTA 2116/4885FNTB 3061/4885MAPT 4859/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | FNTA 1540/4885FNTB 2738/4885MAPT 4530/4885 |
| US-20100256172-A1 | Heteroaryls and uses thereof | PIK3R3, PIK3R1, AKT3 | FNTA 1987/4885FNTB 2772/4885MAPT 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.